Introduction: Preeclampsia is a common pregnancy condition affecting between 3-7% of women. Unfortunately, the exact pathophysiology of the disease is unknown and as such there are no effective treatments that exist notwithstanding prompt delivery of the fetus and culprit placenta. As many cases of preeclampsia occur in preterm pregnancies, it remains a significant cause of both maternal and perinatal morbidity and mortality. Recently, both in vitro and animal studies have highlighted the potential role of antioxidants in mitigating the effects of the disease.
Article focus:
• The aim of the trial is to establish whether melatonin will afford a clinical or biochemical benefit in women with early-onset preeclampsia.
• To test the hypothesis, we will pose the following research aims in pregnancies affected by preterm preeclampsia:
o To determine the effect of daily maternal oral treatment with melatonin on clinical outcomes.
o To determine the effect of daily maternal oral treatment with melatonin on the oxidative stress response in the maternal, placental and fetal circulation.
o To determine the effect of daily maternal oral treatment with melatonin on the clinical and biochemical measures of vascular function in the mother and fetus.
Key messages:
• Preeclampsia is a life-threatening condition for both mother and baby with increased levels of oxidative stress. Unfortunately, despite ongoing advancements in perinatal care, preeclampsia remains an incurable disease.
• Extensive animal studies demonstrate that the use of melatonin as an antioxidant in highrisk pregnancies is very promising and does not harm the developing fetus.
• This study aims to be the first human trial to assess the potential clinical and biochemical effects of melatonin in pregnancies complicated by preterm preeclampsia.
Strengths and limitations of this study:
• The strengths of this trial are that it is an appropriately designed pilot study with realistically set numbers to achieve easily measurable outcomes. Significant preparatory work has been conducted into the preliminary in-vitro and animal studies to guide the trial design. The trial is the first of its type world-wide and if successful, will be able to direct future randomised controlled trials.
• The limitation of this trial is that due to the nature of such a pilot study in pregnant women, the relatively small numbers of participants must act as their own pre-treatment controls. It is predicted that this limitation will be overcome in subsequent trials that will be largely informed by the outcomes of this study. Preeclampsia is a multi-organ syndrome of pregnancy that manifests after 20 weeks gestation with new-onset hypertension alongside maternal end-organ dysfunction and/or intrauterine fetal growth restriction. It affects between 3-7% of all pregnancies and is associated with substantial maternal and perinatal morbidity and mortality, with a significant proportion of fetal complications due to prematurity. To date, the exact pathophysiology of preeclampsia is unknown, but early placental dysfunction plays a central role in all leading hypotheses [1 2 ].
This placental dysfunction is thought to result in a local and systemic cascade of increasing oxidative stress in the mother, leading to endothelial dysfunction and subsequent end-organ consequences.
Placental hypoxia and reperfusion, as a consequence of abnormal placentation, result in oxidative stress leading to apoptotic and necrotic disruption of the syncytial structure. This disruption then results in the release of various factors and compounds from the intervillous space into the maternal circulation that stimulate the production of pro-inflammatory cytokines, such as tumor necrosis factor alpha (TNF alpha), interleukin (IL)-6 and anti-angiogenic factors such as soluble fms-like tyrosine kinase 1 (sFlt1) and soluble endoglin (sEng) [2] . The resultant effect involves potentially widespread increased oxidative stress with anti-angiogenic compromise to the maternal vasculature.
Melatonin (5-methoxy-N-acetyltryptamine) is an endogenous lipid-soluble antioxidant hormone produced primarily by the pineal gland in humans, providing circadian and seasonal timing cues.
In addition, melatonin is also a powerful antioxidant, acting both as a direct scavenger of oxygen free radicals, especially the highly damaging hydroxyl radical, and indirectly via up-regulation of antioxidant enzymes including GSHPx, GSH-reductase, superoxide dismutase and catalase [3 4 ].
Melatonin has several characteristics that make it an appealing treatment for use in pregnancy.
Melatonin freely crosses the placenta [5] and blood-brain barrier [6] , and has an excellent safety profile with no known adverse effects [7 8 ]. Reduced levels of melatonin are found in pregnant women with preeclampsia [9] . Placentae express receptors for melatonin [10] and thus melatonin Our group has previously shown that in an animal model of fetal growth restriction (FGR), melatonin administration reduced fetal hypoxia, improved neurodevelopment and decreased brain injury and oxidative stress in newborn lambs. In another published experiment we administered melatonin shortly before and during a short period of severe fetal asphyxia induced by umbilical cord occlusion at late-gestation. Melatonin prevented the formation of free radicals (hydroxyl radical) within the fetal brains and decreased lipid peroxidation and brain cell death [5] . The protective effects of melatonin on ischemia-reperfusion-induced oxidative damage to mitochondria in the rat placenta have also been published [11] . Melatonin treatment improves placental function (fetal:placental weight ratio), improves birth weight and induces antioxidant enzymes in a rat model of maternal undernourishment, known to promote oxidative stress [12] .
Melatonin has been studied in several clinical trials in humans at varying gestations and for different purposes. Melatonin has been assessed in assisted reproductive technology where the quality of oocytes is important for the success of in-vitro fertilization (IVF). Melatonin is an important compound found in the follicular fluid that has been shown to be important for oocyte maturation and quality, and has been suggested to improve pregnancy outcomes with IVF [13] [14] [15] . To date, no babies born from melatonin-treated pregnancies have been shown to have any increase in abnormalities [16] . Melatonin has also been shown to up-regulate antioxidant enzymes in human pregnancies leading to the conclusion that melatonin might provide an indirect protection against injury caused by reactive oxygen species as seen in preeclampsia, FGR and fetal hypoxia [17] .
Melatonin does not have any acute pharmacological effects in the nervous or vascular systems, apart from its benign but active effect on sleep mechanisms [18] . Mice that have received extremely high doses of up to 800 mg/kg melatonin did not have increased mortality and as such the median lethal dose could not be established. In humans, a Phase II clinical trial conducted in the Netherlands administered 75 mg melatonin nightly to 1400 women over 4-years, with no serious side effects reported [19] . The maternal no-adverse-effect-level (NOAEL) for melatonin 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 [20] .
Rationale
Preeclampsia is a life-threatening condition for both mother and baby affecting up to 7% of pregnancies. Despite ongoing advancements in perinatal care, preeclampsia remains an incurable disease. Extensive animal studies demonstrate that the use of melatonin as an antioxidant in high-risk pregnancies is very promising. Melatonin readily crosses the placenta and does not harm the developing fetus, not even when administered in extremely high doses. This study aims to be the first human trial to assess the potential clinical and biochemical effects of melatonin in pregnancies complicated by preterm preeclampsia.
Aims
The aim of the trial is to establish whether melatonin will afford a clinical or biochemical benefit in women with early-onset preeclampsia. To test the hypothesis, we will pose the following research aims:
To determine the effect of daily maternal oral treatment with melatonin on the clinical outcomes of pregnancies affected by preterm preeclampsia.
2.
To determine the effect of daily maternal oral treatment with melatonin on the oxidative stress response in the maternal, placental and fetal circulation in pregnancies affected by preterm preeclampsia.
3.
To determine the effect of daily maternal oral treatment with melatonin on the clinical and biochemical measures of vascular function in the mother and fetus in pregnancies affected by preterm preeclampsia. 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 
Subjects
We plan to recruit 20 women with preterm preeclampsia.
Study setting
We will recruit patients from the obstetric departments of Monash Health and Jessie McPherson Private Hospitals co-located in Melbourne, Australia.
Sample size
This study is a proof-of-principle Phase I trial and as such a power calculation has not been performed to determine sample size. The purpose of this trial is to establish appropriate outcome measures that can be used to calculate power for a future Phase II randomized-controlled trial for the same intervention. 
Inclusion

Participant enrolment
The PAMPR trial will be introduced to potential trial participants identified from various settings within the trial institutions. The clinical research team will give the potential participant an information sheet about the trial and answer any questions she or her relatives may have.
Maternal and fetal assessments combined with the results of blood tests will determine whether immediate delivery is essential for the survival and wellbeing of mother and baby. If the attending clinician considers delivery within 48 hours as probable, the mother is not eligible for inclusion to the PAMPR trial. Absolute criteria for immediate delivery are not specified in this protocol and remain the responsibility of the attending clinician.
Where delivery within 48 hours is considered unlikely, the women can be approached for consent to the PAMPR trial. Ideally there should be a period of 24 hours for the women to consider whether she wishes to take part in the trial. However, it is considered clinically important to initiate treatment as soon as possible after the diagnosis of preeclampsia, therefore consent should be sought at the earliest opportunity, provided the investigator is reassured that the woman has fully understood the requirements of the trial.
Following admission to the hospital the trial medication will be written on the patient drug chart and administered through usual prescribing practices.
Intervention
Eligible women will receive melatonin (10 mg) tablets three times daily from recruitment until delivery. 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 
Primary outcome
Interval in days from diagnosis with preeclampsia until delivery. Table 3 . Markers of preeclampsia severity. 
Secondary outcomes
Markers of preeclampsia severity
Proposed analyses
The length of gestation post recruitment will be analysed using a t-test. 11 The biomarkers will be analysed using a repeated measures analysis, including the baseline value as a covariate. For the primary analysis the treatment effect will be considered constant over time, secondary analyses will examine the possibility of a trend over time. Plots of mean score over time will be shown for clarification. Initially, the treatment effect will be assumed to be constant over time, but if time by treatment interaction is shown to be important by including this parameter in the model (the conventional level of p=0.05 will be used here) then further investigation into effects at differing time points will be made by analysing the least-square means as above. Plots of mean score over time will be shown for clarification.
Neonatal ouctomes
All other continuous measures (clinical measures, etc) will be considered in the same manner as above (adjusting by baseline value if available). Dichotomous outcomes (mortality, etc) will be presented as risk ratios, with a corresponding chi-squared test performed.
Apart from baseline value, no adjustments for covariates will be made in the first instance in any of the investigations. Treatment estimates will only be adjusted when subgroups are explored.
Interaction between treatment and subgroup variables will be examined in a similar fashion as above by including the relevant parameters in the model. This will be done in turn for each subgroup variable and adjusted estimates presented.
All tests are 2-sided and results will be presented as a point estimate along with 95% confidence intervals.
Adverse events
Participants will be inpatients for the duration of the trial. As such, a senior obstetric clinician who will be in ongoing communication with the research team will see them daily. The principal investigator of the PAMPR trial will be contactable by telephone at all times in the case of an adverse event. Any serious adverse events that occur after joining the trial will be reported in 
Ethics and dissemination
Ethical approval has been obtained from the Monash Health Human Research Ethics Committee B (HREC 13076B). Data will be presented at international conferences and published in peerreviewed journals. We will make the information obtained from the study available to the public through national bodies and charities.
Discussion
If effective, we believe that treatment with melatonin could become standard of care for women with pregnancies complicated by preterm preeclampsia. The potential benefits to both mother and baby would significantly reduce what is a terrible burden of disease internationally.
Treatment with this medication also has potential use in other pregnancy disorders such as FGR and hypoxia.
We do not however, anticipate that this will be the final trial to determine whether further exploration of this area is worthwhile. We hope that the study will generate sufficient evidence that melatonin may be effective; to support a funding application for a larger randomized controlled trial. Such a trial could be designed to test the hypothesis that melatonin treatment in preterm preeclampsia afforded superior and more cost-effective outcomes prioritised by consumer groups and clinicians than existing managements. 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 Running title: A pilot study of antenatal maternally administered melatonin to decrease the level of oxidative stress in human pregnancies affected by preeclampsia: PAMPR trial study protocol.
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Abstract
Introduction: Preeclampsia is a common pregnancy condition affecting between 3-7% of women. Unfortunately, the exact pathophysiology of the disease is unknown and as such there are no effective treatments that exist notwithstanding prompt delivery of the fetus and culprit placenta. As many cases of preeclampsia occur in preterm pregnancies, it remains a significant cause of both maternal and perinatal morbidity and mortality. Recently, both in vitro and animal studies have highlighted the potential role of antioxidants in mitigating the effects of the disease.
Melatonin is a naturally occurring antioxidant hormone and provides an excellent safety profile combined with ease of oral administration. We present the protocol for a Phase I pilot clinical trial investigating the efficacy and side effects of maternal treatment with oral melatonin in pregnancies affected by preterm preeclampsia.
Methods and analysis:
We propose undertaking a single-arm open label clinical trial recruiting 20 women with preterm preeclampsia (24 +0 -35 +6 weeks). We will take baseline measurements of maternal and fetal well-being, levels of oxidative stress, ultrasound Doppler studies and other biomarkers of preeclampsia. Women will then be given oral melatonin (10 mg) three times daily until delivery. The primary outcome will be time interval between diagnosis and delivery compared to historical controls. Secondary outcomes will compare the baseline measurements previously mentioned with twice-weekly measurements during treatment, and then 6 weeks postpartum.
Ethics and dissemination: Ethical approval has been obtained from Monash Health Human
Research Ethics Committee B (HREC 13076B). Data will be presented at international conferences and published in peer-reviewed journals.
Trial registration number: ACTRN12613000476730 (ANZCTR). 
Article Summary
• The limitation of this trial is that due to the nature of such a pilot study in pregnant women, the relatively small numbers of participants must act as their own pre-treatment controls. It is predicted that this limitation will be overcome in subsequent trials that will be largely informed by the outcomes of this study. 
Introduction
Preeclampsia is a multi-organ syndrome of pregnancy that manifests after 20 weeks gestation with new-onset hypertension alongside maternal end-organ dysfunction and/or intrauterine fetal growth restriction [1] . It affects between 3-7% of all pregnancies and is associated with substantial maternal and perinatal morbidity and mortality, with a significant proportion of fetal complications due to prematurity [2] . To date, the exact pathophysiology of preeclampsia is unknown, but early placental dysfunction plays a central role in all leading hypotheses [3 4 ].
Placental hypoxia and reperfusion, as a consequence of abnormal placentation, result in oxidative stress leading to apoptotic and necrotic disruption of the syncytial structure [5] . This disruption then results in the release of various factors and compounds from the intervillous space into the maternal circulation that stimulate the production of pro-inflammatory cytokines, such as tumor necrosis factor alpha (TNF alpha), interleukin (IL)-6 and anti-angiogenic factors such as soluble fms-like tyrosine kinase 1 (sFlt1) and soluble endoglin (sEng) [4] . The resultant effect involves potentially widespread increased oxidative stress with anti-angiogenic compromise to the maternal vasculature.
In addition, melatonin is also a powerful antioxidant, acting both as a direct scavenger of oxygen free radicals, especially the highly damaging hydroxyl radical, and indirectly via up-regulation of antioxidant enzymes including GSHPx, GSH-reductase, superoxide dismutase and catalase [6 7 ].
Melatonin freely crosses the placenta [8] and blood-brain barrier [9] , and has an excellent safety profile with no known adverse effects [10 11 ]. Reduced levels of melatonin are found in pregnant women with preeclampsia [12] . Placentae express receptors for melatonin [13] and thus Our group has previously shown that in an animal model of fetal growth restriction (FGR), melatonin administration reduced fetal hypoxia, improved neurodevelopment and decreased brain injury and oxidative stress in newborn lambs [14] . In another published experiment we administered melatonin shortly before and during a short period of severe fetal asphyxia induced by umbilical cord occlusion at late-gestation. Melatonin prevented the formation of free radicals (hydroxyl radical) within the fetal brains and decreased lipid peroxidation and brain cell death [8] . The protective effects of melatonin on ischemia-reperfusion-induced oxidative damage to mitochondria in the rat placenta have also been published [15] . Melatonin treatment improves placental function (fetal:placental weight ratio), improves birth weight and induces antioxidant enzymes in a rat model of maternal undernourishment, known to promote oxidative stress [16] .
Melatonin has been studied in several clinical trials in humans at varying gestations and for different purposes. Melatonin has been assessed in assisted reproductive technology where the quality of oocytes is important for the success of in-vitro fertilization (IVF). Melatonin is an important compound found in the follicular fluid that has been shown to be important for oocyte maturation and quality, and has been suggested to improve pregnancy outcomes with IVF [17] [18] [19] . To date, no babies born from melatonin-treated pregnancies have been shown to have any increase in abnormalities [20] . Melatonin has also been shown to up-regulate antioxidant enzymes in human pregnancies leading to the conclusion that melatonin might provide an indirect protection against injury caused by reactive oxygen species as seen in preeclampsia, FGR and fetal hypoxia [21] .
Melatonin does not have any acute pharmacological effects in the nervous or vascular systems, apart from its benign but active effect on sleep mechanisms [22] . Mice that have received extremely high doses of up to 800 mg/kg melatonin did not have increased mortality and as such the median lethal dose could not be established [22] . In humans, a Phase II clinical trial conducted in the Netherlands administered 75 mg melatonin nightly to 1400 women over 4years, with no serious side effects reported [23] . The maternal no-adverse-effect-level (NOAEL) 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 
Rationale
Preeclampsia is a life-threatening condition for both mother and baby affecting up to 7% of pregnancies [2] . Despite ongoing advancements in perinatal care, preeclampsia remains an incurable disease. Extensive animal studies demonstrate that the use of melatonin as an antioxidant in high-risk pregnancies is very promising. Melatonin readily crosses the placenta and does not harm the developing fetus, not even when administered in extremely high doses [22] . This study aims to be the first human trial to assess the potential clinical and biochemical effects of melatonin in pregnancies complicated by preterm preeclampsia.
Aims
1.
2.
3.
Subjects
We plan to recruit 20 women with preterm preeclampsia. We will also perform a retrospective review of cases over the previous 24 months to use as historical controls for the primary outcome measure.
Study setting
We will recruit patients from the obstetric departments of Monash Health and Jessie McPherson
Private Hospitals co-located in Melbourne, Australia over a 12-month period.
Sample size
This study is a proof-of-principle Phase I trial and as such a power calculation has not been performed to determine sample size. The purpose of this trial is to establish appropriate outcome measures that can be used to calculate power for a future Phase II randomized-controlled trial for the same intervention. 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 
Inclusion
Participant enrolment
The PAMPR trial will be introduced to potential trial participants identified from routine antenatal clinics, pregnancy assessment units and labour ward admissions within the trial institutions as identified by the Principal Investigator. Maternal and fetal assessments by the treating clinician combined with the results of blood tests will determine whether immediate delivery is essential for the survival and wellbeing of mother and baby. If the treating clinician considers delivery within 48 hours as probable, the mother is not eligible for inclusion to the PAMPR trial. Absolute criteria for immediate delivery are not specified in this protocol and remain the responsibility of the attending clinician.
Where delivery within 48 hours is considered unlikely, the women can be approached for consent to the PAMPR trial. The Principal Investigator will provide written information about
the trial and answer any questions she or her relatives may have. The patient's written informed consent to participate in the trial must be obtained before recruitment and after a full explanation has been given of the treatment options and the manner of treatment administration. Ideally there should be a period of 24 hours for the women to consider whether she wishes to take part in the trial. However, it is considered clinically important to initiate treatment as soon as possible after the diagnosis of preeclampsia, therefore consent should be sought at the earliest opportunity, provided the investigator is reassured that the woman has fully understood the requirements of the trial. Following admission to the hospital the trial medication will be written on the patient drug chart and administered through usual prescribing practices.
The historical controls for the primary outcome measure (interval from diagnosis to delivery) will be obtained through de-identified retrospective review of medical records from Monash
Health over the previous 24-month period. These historical controls will be women diagnosed with preterm preeclampsia who meet the inclusion and exclusion criteria who underwent expectant management.
Intervention
Eligible women will receive melatonin (10 mg) tablets three times daily from recruitment until delivery.
Primary outcome
Interval in days from participant diagnosis with preeclampsia until delivery compared to historical controls. Table 1 . Maternal biomarkers of oxidative stress. 
Secondary outcomes
Maternal biomarkers of oxidative stress
Markers of maternal morbidity
Samples collected at recruitment and then up to every three days until delivery Serum creatinine equal to or >120 micmol/L Proteinuria equal to or >5 g/24h
Hypertension equal to or >170/110 mmHg (despite Rx)
Signs of left ventricular failure
Eclampsia Platelets <50x10 9 /L
Disseminated intravascular coagulation
Cerebrovascular event Liver transaminase equal to or >500 IU/L 
Proposed analyses
The length of gestation post recruitment will be analysed using a t-test.
The biomarkers will be analysed using a repeated measures analysis, including the baseline value as a covariate. For the primary analysis the treatment effect will be considered constant over time, secondary analyses will examine the possibility of a trend over time. Plots of mean score over time will be shown for clarification. Initially, the treatment effect will be assumed to be constant over time, but if time by treatment interaction is shown to be important by including this parameter in the model (the conventional level of p=0.05 will be used here) then further investigation into effects at differing time points will be made by analysing the least-square means as above. Plots of mean score over time will be shown for clarification.
Interaction between treatment and subgroup variables will be examined in a similar fashion as All tests are 2-sided and results will be presented as a point estimate along with 95% confidence intervals.
Adverse events
Trial discontinuation or modification
Participants will be withdrawn from the trial at participant request or if they or their fetus suffer an unexpected serious adverse event as noted above. Worsening preeclampsia is within the natural history of the disease and as such will not be part of discontinuation criteria.
There will be no allowance for modification of the trial intervention.
Ethics and dissemination
Discussion
If effective, we believe that treatment with melatonin could become standard of care for women with pregnancies complicated by preterm preeclampsia. The potential benefits to both mother Treatment with this medication also has potential use in other pregnancy disorders such as FGR and hypoxia.
We do not however, anticipate that this will be the final trial to determine whether further exploration of this area is worthwhile. We hope that the study will generate sufficient evidence that melatonin may be effective; to support a funding application for a larger randomized controlled trial. Such a trial could be designed to test the hypothesis that melatonin treatment in preterm preeclampsia afforded superior and more cost-effective outcomes prioritised by consumer groups and clinicians than existing managements. 
Abstract
Methods and analysis:
Ethics and dissemination: Ethical approval has been obtained from Monash Health Human
Trial registration number: ACTRN12613000476730 (ANZCTR).
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Article Summary
Key messages:
• The limitation of this trial is that due to the nature of such a pilot study in pregnant women, the relatively small numbers of participants must act as their own pre-treatment controls. It is predicted that this limitation will be overcome in subsequent trials that will be largely informed by the outcomes of this study.
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BMJ Open
Melatonin freely crosses the placenta [8] and blood-brain barrier [9] , and has an excellent safety profile with no known adverse effects [10 11 ]. Reduced levels of melatonin are found in pregnant women with preeclampsia [12] . Placentae express receptors for melatonin [13] and thus 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 Our group has previously shown that in an animal model of fetal growth restriction (FGR), melatonin administration reduced fetal hypoxia, improved neurodevelopment and decreased brain injury and oxidative stress in newborn lambs [14] . In another published experiment we administered melatonin shortly before and during a short period of severe fetal asphyxia induced by umbilical cord occlusion at late-gestation. Melatonin prevented the formation of free radicals (hydroxyl radical) within the fetal brains and decreased lipid peroxidation and brain cell death [8] . The protective effects of melatonin on ischemia-reperfusion-induced oxidative damage to mitochondria in the rat placenta have also been published [15] . Melatonin treatment improves placental function (fetal:placental weight ratio), improves birth weight and induces antioxidant enzymes in a rat model of maternal undernourishment, known to promote oxidative stress [16] .
Melatonin does not have any acute pharmacological effects in the nervous or vascular systems, apart from its benign but active effect on sleep mechanisms [22] . Mice that have received extremely high doses of up to 800 mg/kg melatonin did not have increased mortality and as such the median lethal dose could not be established [22] . In humans, a Phase II clinical trial 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 
Rationale
Aims
2.
3.
Subjects
Study setting
Sample size
Inclusion
Participant enrolment
The PAMPR trial will be introduced to potential trial participants identified from routine antenatal clinics, pregnancy assessment units and labour ward admissions within the trial institutions various settings within the trial institutions. The as identified by the Principal Investigator. clinical research team will give the potential participant an information sheet about
the trial and answer any questions she or her relatives may have. Maternal and fetal assessments by the treating clinician combined with the results of blood tests will determine whether immediate delivery is essential for the survival and wellbeing of mother and baby. If the treatingattending clinician considers delivery within 48 hours as probable, the mother is not eligible for inclusion to the PAMPR trial. Absolute criteria for immediate delivery are not specified in this protocol and remain the responsibility of the attending clinician.
the trial and answer any questions she or her relatives may have. The patient's written informed consent to participate in the trial must be obtained before recruitment and after a full explanation has been given of the treatment options and the manner of treatment administration. Ideally there should be a period of 24 hours for the women to consider whether she wishes to take part in the trial. However, it is considered clinically important to initiate treatment as soon as possible after the diagnosis of preeclampsia, therefore consent should be sought at the earliest opportunity, provided the investigator is reassured that the woman has fully understood the requirements of the trial.
Intervention
Primary outcome
Interval in days from participant diagnosis with preeclampsia until delivery compared to historical controls. 
Secondary outcomes
Proposed analyses
Apart from baseline value, no adjustments for covariates will be made in the first instance in any of the investigations. Treatment estimates will only be adjusted when subgroups are explored. 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 Interaction between treatment and subgroup variables will be examined in a similar fashion as above by including the relevant parameters in the model. This will be done in turn for each subgroup variable and adjusted estimates presented.
Neonatal ouctomes
Adverse events
Trial discontinuation or modification
Ethics and dissemination
Ethical approval has been obtained from the Monash Health Human Research Ethics Committee B (HREC 13076B). Data will be presented at international conferences and published in peerreviewed journals. We will make the information obtained from the study available to the public through national bodies and charities. 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 
Discussion
We do not however, anticipate that this will be the final trial to determine whether further exploration of this area is worthwhile. We hope that the study will generate sufficient evidence that melatonin may be effective; to support a funding application for a larger randomized controlled trial. Such a trial could be designed to test the hypothesis that melatonin treatment in preterm preeclampsia afforded superior and more cost-effective outcomes prioritised by consumer groups and clinicians than existing managements.
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